Teplizumab

Drug Profile

Teplizumab

Alternative Names: hOKT3-gamma-1-ala-ala - MacroGenics; hOKT3-γ1-ala-ala; MGA031

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Tolerance Therapeutics
  • Developer Immune Tolerance Network; MacroGenics; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Multiple sclerosis; Psoriasis; Psoriatic arthritis

Most Recent Events

  • 11 May 2015 Teplizumab is still in phase II trials for Type-1 diabetes mellitus (Prevention) in USA and Canada
  • 11 May 2015 Discontinued - Phase-II/III for Type-1 diabetes mellitus in Canada, Sweden, Latvia and Estonia (IV)
  • 11 May 2015 Discontinued - Phase-III for Type-1 diabetes mellitus in Belgium, Czech Republic, Finland, France, Germany, Italy, Netherlands, Poland, Romania, Spain, United Kingdom, Mexico, USA, Israel, India and Ukraine (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top